This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.48% per year. These returns cover a period from January 1, 1988 through May 5, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
gene-therapy: Archive
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
by Zacks Equity Research
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.
LLYPositive Net Change BAYRYPositive Net Change ADMANegative Net Change VERVPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
by Zacks Equity Research
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
DVAXPositive Net Change BAYRYPositive Net Change PCRXNegative Net Change CORTPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
by Zacks Equity Research
The EMA pauses all clinical studies of Sarepta and Roche's Elevidys following the reported death of a treated patient
RHHBYPositive Net Change SRPTNegative Net Change ANIPNegative Net Change CTMXPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Clearway Energy (CWEN)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CWENPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Information Services Group (III) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IIIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
by Sundeep Ganoria
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
MRNANegative Net Change NVAXNegative Net Change SRPTNegative Net Change CRSPPositive Net Change PCVXNo Net Change
biotechs gene-editing gene-therapy medical messenger-rna vaccines
Sky Harbour Group Corporation (SKYH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SKYHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
by Urmimala Biswas
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
REGNPositive Net Change ALCPositive Net Change GKOSPositive Net Change
cell-therapy gene-therapy medical medical-devices pharmaceuticals
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
ILMNPositive Net Change BEAMNegative Net Change WVEPositive Net Change NTLAPositive Net Change CRSPPositive Net Change TWSTPositive Net Change
biotechnology biotechs gene-editing gene-therapy genetic-testing genomics medical
Groupon (GRPN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GRPNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ADMANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ANIPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
by Sundeep Ganoria
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
RHHBYPositive Net Change SRPTNegative Net Change PTCTPositive Net Change ARWRPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
Novartis Reports Updated Positive Data From Phase III SMA Program
by Zacks Equity Research
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
NVSPositive Net Change RHHBYPositive Net Change DVAXPositive Net Change GILDNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
by Zacks Equity Research
Despite the reported death, Sarepta maintains that its gene therapy has a favorable 'benefit-risk profile.'
RHHBYPositive Net Change SRPTNegative Net Change ANIPNegative Net Change CTMXPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.
VRTXPositive Net Change BEAMNegative Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs crispr gene-therapy medical
Astronics Corporation (ATRO)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ATRONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
WK Kellogg (KLG) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
KLGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Evertec (EVTC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
EVTCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
by Zacks Equity Research
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.
BIIBPositive Net Change RHHBYPositive Net Change SRPTNegative Net Change SLDBPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.
BMRNPositive Net Change GILDNegative Net Change VRTXPositive Net Change EDITPositive Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
EverQuote (EVER) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
EVERNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Option Care (OPCH)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
OPCHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Annaly Capital Management (NLY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
NLYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy First Industrial Realty Trust (FR) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines